Glenview State Bank Trust DEPT. raised its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 9.5% during the third quarter, Holdings Channel reports. The fund owned 26,954 shares of the biopharmaceutical company’s stock after buying an additional 2,336 shares during the period. Glenview State Bank Trust DEPT.’s holdings in Gilead Sciences were worth $2,133,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of GILD. M&R Capital Management Inc. raised its position in Gilead Sciences by 6.1% in the first quarter. M&R Capital Management Inc. now owns 10,905 shares of the biopharmaceutical company’s stock worth $1,002,000 after buying an additional 625 shares during the period. Clear Harbor Asset Management LLC raised its position in shares of Gilead Sciences by 31.8% in the first quarter. Clear Harbor Asset Management LLC now owns 15,073 shares of the biopharmaceutical company’s stock worth $1,385,000 after buying an additional 3,635 shares during the last quarter. Lyons Wealth Management LLC. raised its position in shares of Gilead Sciences by 10.9% in the first quarter. Lyons Wealth Management LLC. now owns 9,249 shares of the biopharmaceutical company’s stock worth $846,000 after buying an additional 906 shares during the last quarter. First Republic Investment Management Inc. raised its position in shares of Gilead Sciences by 14.7% in the first quarter. First Republic Investment Management Inc. now owns 733,366 shares of the biopharmaceutical company’s stock worth $67,367,000 after buying an additional 93,775 shares during the last quarter. Finally, Cullinan Associates Inc. raised its position in shares of Gilead Sciences by 33.0% in the first quarter. Cullinan Associates Inc. now owns 49,922 shares of the biopharmaceutical company’s stock worth $4,586,000 after buying an additional 12,390 shares during the last quarter. 73.59% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.56% during midday trading on Wednesday, hitting $73.70. 10,627,256 shares of the company traded hands. The stock has a 50 day moving average of $74.54 and a 200-day moving average of $80.07. The stock has a market capitalization of $97.10 billion, a PE ratio of 6.81 and a beta of 1.25. Gilead Sciences Inc. has a 52 week low of $71.39 and a 52 week high of $108.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. The company earned $7.40 billion during the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. Gilead Sciences’s quarterly revenue was down 9.6% compared to the same quarter last year. During the same period last year, the firm posted $3.22 earnings per share. Equities analysts forecast that Gilead Sciences Inc. will post $11.47 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.55%. The ex-dividend date of this dividend is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 17.44%.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Financial Market News and is the propert of of Financial Market News. If you are viewing this report on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The original version of this report can be read at http://www.financial-market-news.com/glenview-state-bank-trust-dept-has-2133000-position-in-gilead-sciences-inc-gild/1211344/.

A number of brokerages have recently issued reports on GILD. Piper Jaffray Cos. set a $108.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Sunday, August 21st. Cowen and Company set a $120.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Sunday, October 23rd. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Sunday, November 6th. Stifel Nicolaus reiterated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Wednesday. Finally, Zacks Investment Research upgraded shares of Gilead Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, November 7th. Ten investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $97.90.

In other news, Director John W. Madigan sold 105,000 shares of the stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the sale, the director now directly owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John C. Martin sold 100,000 shares of the stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the completion of the sale, the insider now directly owns 3,287,810 shares in the company, valued at $254,739,518.80. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.